Potential problems in the use of commercial preparations of radiolabeled cholesterol

Florence H. Mahlberg; Annabelle Rodriguez-Oquendo; David W. Bernard; Jane M. Glick; George H. Rothblat

doi:10.1016/0021-9150(90)90078-W

Potential problems in the use of commercial preparations of radiolabeled cholesterol

Florence H. Mahlberg, Annabelle Rodriguez-Oquendo, David W. Bernard, Jane M. Glick, George H. Rothblat

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Through a series of biological and analytical procedures, we demonstrate that a compound purchased from a commercial supplier as [7-³H]cholesterol was not cholesterol. In mouse peritoneal macrophages, this compound was metabolized differently than other radiolabeled cholesterol preparations and was accumulated in the steryl ester pool. In contrast, Fu5AH rat hepatoma cells did not discriminate this compound from cholesterol. Further analysis of the anomalous [7-3H]cholesterol by TLC after cholesterol oxidase treatment and by HPLC indicated that this radiochemical was less polar than cholesterol standard and other radiolabeled cholesterol preparations tested. Mass spectrometry analysis disclosed that the chemical has a similar fragmentation pattern avnd the same molecular weight (386) as cholesterol.

Original language	English (US)
Pages (from-to)	95-100
Number of pages	6
Journal	Atherosclerosis
Volume	84
Issue number	2-3
DOIs	https://doi.org/10.1016/0021-9150(90)90078-W
State	Published - Oct 1990

Keywords

Cholesterol
Commercial cholesterol preparations
Radiolabeled cholesterol

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/0021-9150(90)90078-W

Cite this

@article{fb17d0c3e5b348d3ae791426efbd7849,

title = "Potential problems in the use of commercial preparations of radiolabeled cholesterol",

abstract = "Through a series of biological and analytical procedures, we demonstrate that a compound purchased from a commercial supplier as [7-3H]cholesterol was not cholesterol. In mouse peritoneal macrophages, this compound was metabolized differently than other radiolabeled cholesterol preparations and was accumulated in the steryl ester pool. In contrast, Fu5AH rat hepatoma cells did not discriminate this compound from cholesterol. Further analysis of the anomalous [7-3H]cholesterol by TLC after cholesterol oxidase treatment and by HPLC indicated that this radiochemical was less polar than cholesterol standard and other radiolabeled cholesterol preparations tested. Mass spectrometry analysis disclosed that the chemical has a similar fragmentation pattern avnd the same molecular weight (386) as cholesterol.",

keywords = "Cholesterol, Commercial cholesterol preparations, Radiolabeled cholesterol",

author = "Mahlberg, {Florence H.} and Annabelle Rodriguez-Oquendo and Bernard, {David W.} and Glick, {Jane M.} and Rothblat, {George H.}",

note = "Funding Information: We are very grateful to Dr. Jerrold M. Liesch for performing mass spectrometry analysis. This work was supported by Program Project Grant HL-22633 and Training Grant HL-07443 from the National Heart, Lung and Blood Institute of the National Institutes of Health. F.H.M. was partly supported by a grant from the ComitC des Aides A la Recherche Fournier-Dijon-France and by the Heinz Foundation. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1990",

month = oct,

doi = "10.1016/0021-9150(90)90078-W",

language = "English (US)",

volume = "84",

pages = "95--100",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2-3",

}

TY - JOUR

T1 - Potential problems in the use of commercial preparations of radiolabeled cholesterol

AU - Mahlberg, Florence H.

AU - Rodriguez-Oquendo, Annabelle

AU - Bernard, David W.

AU - Glick, Jane M.

AU - Rothblat, George H.

N1 - Funding Information: We are very grateful to Dr. Jerrold M. Liesch for performing mass spectrometry analysis. This work was supported by Program Project Grant HL-22633 and Training Grant HL-07443 from the National Heart, Lung and Blood Institute of the National Institutes of Health. F.H.M. was partly supported by a grant from the ComitC des Aides A la Recherche Fournier-Dijon-France and by the Heinz Foundation. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1990/10

Y1 - 1990/10

N2 - Through a series of biological and analytical procedures, we demonstrate that a compound purchased from a commercial supplier as [7-3H]cholesterol was not cholesterol. In mouse peritoneal macrophages, this compound was metabolized differently than other radiolabeled cholesterol preparations and was accumulated in the steryl ester pool. In contrast, Fu5AH rat hepatoma cells did not discriminate this compound from cholesterol. Further analysis of the anomalous [7-3H]cholesterol by TLC after cholesterol oxidase treatment and by HPLC indicated that this radiochemical was less polar than cholesterol standard and other radiolabeled cholesterol preparations tested. Mass spectrometry analysis disclosed that the chemical has a similar fragmentation pattern avnd the same molecular weight (386) as cholesterol.

AB - Through a series of biological and analytical procedures, we demonstrate that a compound purchased from a commercial supplier as [7-3H]cholesterol was not cholesterol. In mouse peritoneal macrophages, this compound was metabolized differently than other radiolabeled cholesterol preparations and was accumulated in the steryl ester pool. In contrast, Fu5AH rat hepatoma cells did not discriminate this compound from cholesterol. Further analysis of the anomalous [7-3H]cholesterol by TLC after cholesterol oxidase treatment and by HPLC indicated that this radiochemical was less polar than cholesterol standard and other radiolabeled cholesterol preparations tested. Mass spectrometry analysis disclosed that the chemical has a similar fragmentation pattern avnd the same molecular weight (386) as cholesterol.

KW - Cholesterol

KW - Commercial cholesterol preparations

KW - Radiolabeled cholesterol

UR - http://www.scopus.com/inward/record.url?scp=0025012343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025012343&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(90)90078-W

DO - 10.1016/0021-9150(90)90078-W

M3 - Article

C2 - 2282104

AN - SCOPUS:0025012343

VL - 84

SP - 95

EP - 100

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2-3

ER -

Potential problems in the use of commercial preparations of radiolabeled cholesterol

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this